Henlius Speeds Up Efforts On Ophthalmic Bevacizumab

Phase III Trial Begins As Chinese Firm Works With Partner Essex On Global Filings

 
• By Dave Wallace

Shanghai Henlius Biotech has revealed the latest update on its proposed ophthalmic version of biosimilar bevacizumab, with a global Phase III trial beginning as the firm also pursues international filings with partner Essex Bio-Technology.

Eye Data Ophthalmic
Henlius is eyeing several marketing authorization applications • Source: Sergey Nivens

Shanghai Henlius Biotech has announced the latest advance in its development program for an ophthalmic version of biosimilar bevacizumab, after the first patient was dosed in a global, multi-center Phase III clinical trial for its HLX04-O candidate.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products